HCW Biologics (HCWB) Q2 2025 earnings summary

Executive summary

• Net loss for Q2 2025 was $1.9M, a significant improvement from $15.3M in Q2 2024, mainly due to lower legal expenses and reduced R&D costs.

• Revenues for Q2 2025 were $6.6K, down from $618.9K in Q2 2024, reflecting the suspension of the Wugen license agreement.

• The company executed a $5M equity offering, restructured or extinguished $7.7M of debt, and regained compliance with all Nasdaq listing requirements.

• Remains on track to initiate a Phase 1 clinical trial for HCW9302 in Q3 2025.

• Substantial doubt remains about the company's ability to continue as a going concern due to limited liquidity and ongoing operating losses.

Financial highlights

• Q2 2025 revenues: $6.6K (Q2 2024: $618.9K); H1 2025 revenues: $11.6K (H1 2024: $1.75M).

• Q2 2025 net loss: $1.9M (Q2 2024: $15.3M); H1 2025 net loss: $4.1M (H1 2024: $22.7M).

• Legal expenses dropped sharply to $142.5K–$143K in Q2 2025 from $10.4M in Q2 2024.

• R&D expenses decreased 40% year-over-year in Q2 2025, mainly due to lower manufacturing and preclinical costs.

• Cash and cash equivalents at June 30, 2025: $2.4M (Dec 31, 2024: $4.7M).

Outlook and guidance

• The company expects no revenue from the Wugen license for the next year due to its suspension.

• Management is actively seeking new licensing partners and business development transactions.

• If additional capital is not raised, management may need to revise the business plan and reduce costs.

• Regained compliance with all Nasdaq Capital Market listing requirements as of June 2025, subject to a one-year Panel Monitor.